BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 07, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Contrave regulatory update

FDA issued a complete response letter for Orexigen's obesity candidate Contrave. According to Orexigen, the agency said the company must conduct a cardiovascular outcomes trial to show that the risk of major adverse cardiovascular events in patients receiving Contrave does not adversely affect the drug's benefit-risk profile. FDA also requested a postmarketing drug-drug interaction study of the effects of Contrave...

Read the full 277 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >